408 related articles for article (PubMed ID: 27884974)
1. From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.
Vannucchi AM
Haematologica; 2017 Jan; 102(1):18-29. PubMed ID: 27884974
[TBL] [Abstract][Full Text] [Related]
2. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia vera: diagnosis, clinical course, and current management.
Büyükaşik Y; Alİ R; Ar C; Turgut M; Yavuz S; Saydam G
Turk J Med Sci; 2018 Aug; 48(4):698-710. PubMed ID: 30114348
[TBL] [Abstract][Full Text] [Related]
4. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
5. How to Treat Essential Thrombocythemia and Polycythemia Vera.
Besses C; Alvarez-Larrán A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S114-23. PubMed ID: 27521307
[TBL] [Abstract][Full Text] [Related]
6. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
[TBL] [Abstract][Full Text] [Related]
7. How I treat polycythemia vera.
Vannucchi AM
Blood; 2014 Nov; 124(22):3212-20. PubMed ID: 25278584
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and therapy of polycythemia vera.
Lengfelder E; Merx K; Hehlmann R
Semin Thromb Hemost; 2006 Apr; 32(3):267-75. PubMed ID: 16673281
[TBL] [Abstract][Full Text] [Related]
9. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
10. Austrian recommendations for the management of polycythemia vera.
Burgstaller S; Buxhofer-Ausch V; Sliwa T; Beham-Schmid C; Gastl G; Geissler K; Melchardt T; Krauth M; Krippl P; Petzer A; Rumpold H; Wölfler A; Gisslinger H
Wien Klin Wochenschr; 2018 Sep; 130(17-18):535-542. PubMed ID: 30027395
[TBL] [Abstract][Full Text] [Related]
11. New Therapeutic Approaches in Polycythemia Vera.
Falchi L; Newberry KJ; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
13. Advances in understanding and management of polycythemia vera.
Vannucchi AM; Guglielmelli P
Curr Opin Oncol; 2010 Nov; 22(6):636-41. PubMed ID: 20805747
[TBL] [Abstract][Full Text] [Related]
14. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
15. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
16. Management of hydroxyurea resistant or intolerant polycythemia vera.
Raman I; Pasricha SR; Prince HM; Yannakou CK
Leuk Lymphoma; 2021 Oct; 62(10):2310-2319. PubMed ID: 33949918
[TBL] [Abstract][Full Text] [Related]
17. Polycythemia Vera.
Spivak JL
Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
[TBL] [Abstract][Full Text] [Related]
18. Treatment of polycythemia vera.
Dulíček P
Vnitr Lek; 2018; 64(10):955-960. PubMed ID: 30590943
[TBL] [Abstract][Full Text] [Related]
19. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
Lengfelder E
Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
